Sergio Marullo to lead Angelini Pharma, accelerating Brain Health

Angelini Pharma has tapped Sergio Marullo di Condojanni as its new chief executive, a move that places the head of the family’s industrial group at the centre of a refreshed healthcare strategy. The appointment folds leadership of the pharmaceutical arm into the remit of the existing group chief executive to speed decisions and align corporate governance with commercial execution.

The dual mandate follows a period of expansion for Angelini Industries, which reports about €1.6 billion in revenues and operations across 21 countries. The healthcare-focused unit, Angelini Pharma, operates in roughly 20 countries and employs more than 3,000 people. Management says the consolidation is intended to sharpen the group’s resources behind high-priority therapeutic areas.

In his new role, Marullo di Condojanni will prioritise growth in the company’s core specialty, Brain Health, with explicit emphasis on rare neurological disorders and epilepsy. The company has been actively building a diversified pipeline that includes small molecules, biologics and antisense oligonucleotides; recent strategic collaborations include deals with Sovargen, GRIN Therapeutics, OmniAb, Cureverse and JCR Pharmaceuticals.

Leadership changes are accompanied by an operational redesign that creates dedicated franchises to accelerate value capture and international roll‑out. The group also continues to back innovation via corporate venture capital: Angelini Ventures was launched with a €300 million mandate to seed biotech and medtech partnerships and bolt-on opportunities.

Industry context underlines the rationale. Brain health conditions — neurological and mental disorders taken together — affect hundreds of millions in Europe and beyond and represent a persistent unmet-need category. Estimates point to large patient populations and substantial societal costs, which have driven increased investor and corporate attention to neurology R&D and specialist M&A.

Operationally, the new CEO brings a mix of governance and financial experience. As group CEO since 2020, Marullo di Condojanni guided international expansion and revenue growth, and has held senior roles in the Italian financial sector and academic appointments. The board has also announced that former pharma chief Jacopo Andreose will transition to a board and senior advisory role.

Market implications are clear: centralising executive control can reduce time-to-decision on licensing, partnerships and acquisitions — levers that Angelini intends to use to accelerate its global footprint. Observers will watch closely whether the integrated leadership model translates into faster deal-making, deeper pipeline advancement and expanded presence in high-growth neurology markets.